Global Neuroendocrine Tumor Treatment Market: Industry Analysis and Forecast (2020-2026) By Product, Indication, End-Users and Region

Global Neuroendocrine Tumor Treatment Market is expected to reach US$ 2.2 Bn. at a CAGR of 10.11 during the forecast period 2026.

Global Neuroendocrine Tumor Treatment Market Overview:

The improper growth of neoplasms that arise from cells of the numerous endocrine glands and neurological systems causes neuroendocrine tumours. These are commonly called carcinoid tumours because they get infected first in the intestine.

Global Neuroendocrine Tumor Treatment Market Dynamics:

Increasing prevalence of Neuroendocrine Tumor is expected to propel the market growth. Increased incidences of neuroendocrine tumours (NETs) are predicted to boost demand for treatment options, boosting the market growth during the forecast period. Novel therapeutics and diagnostic products are being developed at a rapid pace in this field. Neurofibromatosis type 1 (NF1), Multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2), Von Hippel- tuberous sclerosis complex (TSC) and Lindau syndrome (VHL) disease are all increasing the incidence and prevalence of neuroendocrine tumours (NETs) in the United States. Furthermore, according to a study published in the JAMA Oncology Journal in 2017, the survival rate of all neuroendocrine tumour treatments have improved, particularly in the treatment of distant-stage gastrointestinal neuroendocrine tumours and pancreatic neuroendocrine tumours. This is mostly due to the availability of effective medicines and early disease detection. The market for neuroendocrine tumour treatment is predicted to grow due to the development of new medications. Cancer can be treated in a variety of ways. One of the most popular treatment options for neuroendocrine tumours is targeted therapy. Cancer treatment that uses targeted therapy is quite effective. As a result, targeted NET therapies are predicted to become more popular in the forecast years. Over the forecast period, the market is expected to grow due to an increase in the number of pharmacological approvals for the treatment of neuroendocrine tumours. For example, in January 2018, Novartis Groupe S.A.'s Advanced Accelerator Applications received FDA approval of its new drug application (NDA) for Lutathera for the treatment of Somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), which include foregut, midgut, and hindgut neuroendocrine tumours. The report has profiled eighteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Neuroendocrine Tumor Treatment Market Segment Analysis:

The Global Neuroendocrine Tumor Treatment Market is segmented on the basis of Product, Indication and End-users. Based on Product, the Somatostanin Analogs segment is expected to dominate the global market during the forecast period. Somatostanin Analogs (SSAs) are the most commonly utilized medications to treat neuroendocrine carcinoma because they reduce cancer growth, symptoms, and target biomarkers. Because of the safe treatment procedures provided by SSAs, they account for the biggest revenue share. SSAs are commonly utilized to treat patients who have failed to respond to radiation therapy or surgery. As a result, many SSAs are now in clinical trials and awaiting clearance, and the market is likely to grow rapidly over the forecast period. Tarveda Therapeutics' PEN-221 and Dauntless Pharmaceuticals' DP1038 are two examples. Drugs like Sunitinib and Everolimus are used in targeted therapy. These medications are used as the first line of therapy for neuroendocrine carcinoma since they have less negative effects. Chemotherapy, radiation therapy, surgery, and tyrosine kinase inhibitors are among the additional products available. Global Neuroendocrine Tumor Treatment Market To know about the Research Methodology :- Request Free Sample Report Based on Indication, the gastrointestinal segment accounted for the dominant segment in 2019 as NETs are more likely to arise in the GI tract. According to data provided in a Novartis investor presentation in 2015, GI tumours account for 61% of all NETs, with the small intestine tumour being the most common. According to the American Society of Clinical Oncology (ASCO), roughly 8,000 persons in the United States have diagnosed with GI tract-carcinid tumours in 2016. Over the projected period, the rising occurrence of carcinoid tumours in the GI tract is expected to propel the segment forward.

Global Neuroendocrine Tumor Treatment Market Regional Insights:

Global Neuroendocrine Tumor Treatment Market Regional Insights North America is expected to dominate the global market throughout the forecast period. Because of the increased frequency of neuroendocrine illnesses, developed health care infrastructure, strong clinical pipeline, high level of awareness among individuals, and presence of significant market participants, North America dominates the neuroendocrine tumours market. In this area, there are also supporting insurance programmes, such as Medicare, Medicaid, and Tricare, which make neuroendocrine treatment grow during forecast years. For example, Ipsen got FDA clearance for its Somatuline Depot (lanreotide) Injection 120 mg in December 2014, which is approved for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally progressed or metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs). In addition, the European neuroendocrine tumour therapy market is predicted to grow significantly over the forecast period, owing to an increase in product approvals by the European Commission (EC) for marketing in European countries. The report also helps in understanding Global Neuroendocrine Tumor Treatment Market dynamics, structure by analyzing the market segments and project the Global Neuroendocrine Tumor Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Neuroendocrine Tumor Treatment Market make the report investor’s guide.

Global Neuroendocrine Tumor Treatment Market Scope: Inquire before buying

Global Neuroendocrine Tumor Treatment Market

Global Neuroendocrine Tumor Treatment Market, by Region:

• North America • Europe • South America • MEA • APAC

Global Neuroendocrine Tumor Treatment Market, Key players:

• Novartis AG • Boehringer Ingelheim International GmbH • Pfizer, Inc. • Ipsen Pharma • AVEO Oncology • Hutchison MediPharma Limited • Progenics Pharmaceuticals • F. Hoffmann-La Roche Ltd • Bristol-Myers Squibb Company • Viatris Inc. • Thermo Fisher Scientific Inc. • Regeneron Pharmaceuticals, Inc. • Sun Pharmaceutical Industries Ltd. • Teva Pharmaceutical Industries Ltd. • Eli Lilly and Company • LUPIN • Advanced Accelerator Applications • BioSynthema Inc.
1.Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Neuroendocrine Tumor Treatment Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2019 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Neuroendocrine Tumor Treatment Market 3.4. Geographical Snapshot of the Neuroendocrine Tumor Treatment Market, By Manufacturer share 4. Global Neuroendocrine Tumor Treatment Market Overview, 2019-2026 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Neuroendocrine Tumor Treatment Market 5. Supply Side and Demand Side Indicators 6. Global Neuroendocrine Tumor Treatment Market Analysis and Forecast, 2019-2026 6.1. Global Neuroendocrine Tumor Treatment Market Size & Y-o-Y Growth Analysis. 7. Global Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 7.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 7.1.1. Somatostatin Analogs (SSAs) 7.1.2. Targeted Therapy 7.1.3. Chemotherapy 7.1.4. Others 7.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 7.2.1. Lungs 7.2.2. Pancreas 7.2.3. Gastrointestinal 7.2.4. Others 7.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 7.3.1. Hospitals 7.3.2. Clinics 7.3.3. Others 8. Global Neuroendocrine Tumor Treatment Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2019-2026 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 9.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 9.1.1. Somatostatin Analogs (SSAs) 9.1.2. Targeted Therapy 9.1.3. Chemotherapy 9.1.4. Others 9.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 9.2.1. Lungs 9.2.2. Pancreas 9.2.3. Gastrointestinal 9.2.4. Others 9.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 9.3.1. Hospitals 9.3.2. Clinics 9.3.3. Others 10. North America Neuroendocrine Tumor Treatment Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 11.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 11.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 11.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 12. Canada Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 12.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 12.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 12.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 13. Mexico Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 13.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 13.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 13.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 14. Europe Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 14.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 14.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 14.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 15. Europe Neuroendocrine Tumor Treatment Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 16.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 16.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 16.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 17. France Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 17.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 17.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 17.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 18. Germany Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 18.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 18.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 18.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 19. Italy Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 19.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 19.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 19.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 20. Spain Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 20.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 20.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 20.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 21. Sweden Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 21.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 21.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 21.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 22. CIS Countries Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 22.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 22.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 22.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 23. Rest of Europe Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 23.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 23.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 23.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 24. Asia Pacific Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 24.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 24.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 24.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 25. Asia Pacific Neuroendocrine Tumor Treatment Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 26.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 26.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 26.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 27. India Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 27.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 27.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 27.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 28. Japan Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 28.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 28.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 28.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 29. South Korea Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 29.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 29.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 29.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 30. Australia Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 30.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 30.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 30.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 31. ASEAN Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 31.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 31.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 31.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 32. Rest of Asia Pacific Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 32.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 32.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 32.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 33. Middle East Africa Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 33.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 33.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 33.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 34. Middle East Africa Neuroendocrine Tumor Treatment Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 35.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 35.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 35.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 36. GCC Countries Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 36.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 36.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 36.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 37. Egypt Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 37.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 37.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 37.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 38. Nigeria Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 38.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 38.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 38.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 39. Rest of ME&A Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 39.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 39.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 39.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 40. South America Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 40.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 40.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 40.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 41. South America Neuroendocrine Tumor Treatment Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 42.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 42.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 42.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 43. Argentina Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 43.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 43.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 43.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 44. Rest of South America Neuroendocrine Tumor Treatment Market Analysis and Forecasts, 2019-2026 44.1. Market Size (Value) Estimates & Forecast By Product, 2019-2026 44.2. Market Size (Value) Estimates & Forecast By Indication, 2019-2026 44.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Neuroendocrine Tumor Treatment Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment 45.2.2. New Product Launches and Product Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. Novartis AG 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Product Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. Boehringer Ingelheim International GmbH 45.3.3. Pfizer, Inc. 45.3.4. Ipsen Pharma 45.3.5. AVEO Oncology 45.3.6. Hutchison MediPharma Limited 45.3.7. Progenics Pharmaceuticals 45.3.8. F. Hoffmann-La Roche Ltd 45.3.9. Bristol-Myers Squibb Company 45.3.10. Viatris Inc. 45.3.11. Thermo Fisher Scientific Inc. 45.3.12. Regeneron Pharmaceuticals, Inc. 45.3.13. Sun Pharmaceutical Industries Ltd. 45.3.14. Teva Pharmaceutical Industries Ltd. 45.3.15. Eli Lilly and Company 45.3.16. LUPIN 45.3.17. Advanced Accelerator Applications 45.3.18. BioSynthema Inc. 46. Primary Key Insights

About This Report

Report ID 110060
Category Healthcare
Published Date Jun 2021
Updated Date
Contact Us